Evogene to Present AI Innovations at BIO-Europe Spring 2026 Conference in Lisbon

Evogene Showcases AI-Driven Innovations at BIO-Europe Spring 2026 Conference

Evogene Ltd. announces its participation in the highly anticipated BIO-Europe Spring 2026 conference, running from March 23 to 25 in Lisbon, Portugal. The company, a frontrunner in computational chemistry, particularly emphasizes generative AI for small molecule design, catering to both the pharmaceutical and agricultural sectors. Representing a pivotal opportunity for networking and collaboration, Dr. Gabi Tarcic, Chief Development Officer, and Dr. Olga Nissan, VP of Business Development, will attend to share insights on the company’s latest advancements in AI-driven drug discovery.

Dr. Nissan plans to deliver an insightful oral presentation on March 24, where she will highlight Evogene’s innovative capabilities, particularly the transformations brought forth by ChemPass AI™. This advanced platform facilitates collaborative drug discovery, enabling meaningful partnerships with pharma and biotech firms. Attendees are encouraged to engage with Evogene’s representatives for one-on-one discussions about potential collaborations or projects, emphasizing the company’s active outreach within the industry.

Evogene’s use of ChemPass AI™ allows for the exploration of vast chemical spaces while optimizing small molecules against essential development parameters. This strategic integration of AI technology not only enhances efficiency but also significantly improves the success rates of drug development. By combining advanced computational techniques with experimental validation, Evogene stands at the forefront of innovation, committed to developing groundbreaking solutions that tackle pressing industry challenges. The presentation at the conference is expected to demonstrate the impact of these innovations and further solidify Evogene's position as a leader in molecular design.

In addition to showcasing their technological advancements, Evogene’s participation in BIO-Europe Spring 2026 aligns with its mission to drive future developments within the pharmaceutical sector. The company emphasizes the importance of fostering relationships with industry stakeholders to effectively navigate and address real-world challenges within drug discovery.

As Evogene gears up for this significant event, it also anticipates engaging in fruitful discussions around its roadmap and future initiatives within the pharma division. Interested participants can register for the conference via the link provided, while more information about Evogene’s offerings is available on their official website. Through these endeavors, the company continues to forge pathways toward innovation and success in the computational chemistry landscape.